Tetracycline Versus Doxycycline for HP Rescue Therapy | NCT05018923 | Trialant

Tetracycline Versus Doxycycline for HP Rescue Therapy | NCT05018923 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
RBMD group	Experimental	Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days	Drug: Rabeprazole Drug: Bismuth potassium citrate Drug: Metronidazole Drug: Doxycycline
RAMT group	Active Comparator	Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and tetracycline 0.5 g qid for 14 days	Drug: Rabeprazole Drug: Bismuth potassium citrate Drug: Metronidazole Drug: Tetracycline

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Eradication rate of Helicobacter pylori	Eradication of Helicobacter pylori was defined as negative result of urea breath test (<4‰ cut-off value).	At least 4 weeks after completion of therapy

Secondary Outcomes

Measure	Description	Time Frame
Eradication rate of Helicobacter pylori resistant strains	Eradication of Helicobacter pylori was defined as negative result of urea breath test (<4‰ cut-off value). The antibiotic resistant strains were assessed using the E test method.	At least 4 weeks after completion of therapy
Eradication rate of Helicobacter pylori susceptible strains

Other Outcomes

Measure	Description	Time Frame
Adherence rate	Adherence was defined as poor when subjects took less than 80% of the total medication.	2 weeks during therapy
Frequency of adverse events	Any possible adverse events during the 14-day treatment period were recorded.

Contacts/Locations Module

Intervention Browse Module